Valuation: Prenetics Global Limited

Market Cap 412M 359M 339M 308M 578M 39.5B 579M 4.05B 1.56B 20.12B 1.55B 1.51B 64.92B P/E 2026 *
-7.03x
P/E 2027 * -17.3x
Enterprise Value 412M 359M 339M 308M 578M 39.5B 579M 4.05B 1.56B 20.12B 1.55B 1.51B 64.92B EV / Sales 2026 *
1.84x
EV / Sales 2027 * 1.02x
Free-Float
85.46%
Yield 2026 *
-
Yield 2027 * -
1 day+0.62%
1 week+0.91%
Current month-7.28%
1 month+20.50%
3 months+18.73%
6 months+24.06%
Current year+54.54%
1 week 21.55
Extreme 21.55
25.01
1 month 19.13
Extreme 19.13
27.24
Current year 14
Extreme 14
27.24
1 year 11.36
Extreme 11.365
27.24
3 years 2.85
Extreme 2.85
27.24
5 years 2.85
Extreme 2.85
131.25
10 years 2.85
Extreme 2.85
131.25
Manager TitleAgeSince
Chief Tech/Sci/R&D Officer 52 01/01/2014
Chief Executive Officer 47 01/01/2014
Director of Finance/CFO 41 01/01/2018
Director TitleAgeSince
Chairman 47 01/01/2014
Director/Board Member 38 -
Director/Board Member - 16/02/2026
Date Insider Type Main position Quantity % Market Cap. Importance
04/09/26 Exercice

Director

4,000 0.0257%
25/08/26 Buy

CFO of IM8 (US) LLC

5,100 0.0328%
24/08/26 Buy

Chief Executive Officer

17,181 0.1104%
Change 5-day change 1-year change 3-year change Capi.($)
+0.62%+0.91%+102.83%+248.15% 412M
+0.36%-0.11%-24.30%+4.09% 178B
-0.41%-2.19%-3.50%+14.03% 117B
+2.50%-2.99%+9.13%+71.14% 60.39B
-0.13%-1.21%-3.39%-31.82% 49.22B
-0.22%+0.78%+10.27%+47.46% 48.02B
-0.20%+5.30%+32.20%+0.10% 33.65B
+1.01%-1.93% - - 28.04B
-0.15%+1.85%+41.96%-3.34% 25.46B
-0.69%+5.26%+8.20%-12.97% 22.5B
Average +0.26%+1.16%+19.27%+37.43% 56.32B
Weighted average by Cap. +0.27%-0.14%-2.78%+13.29%

Financials

2026 *2027 *
Net sales 224M 195M 184M 167M 314M 21.45B 314M 2.2B 849M 10.93B 841M 823M 35.27B 404M 352M 331M 302M 566M 38.67B 567M 3.97B 1.53B 19.7B 1.52B 1.48B 63.57B
Net income -61.71M -53.81M -50.68M -46.15M -86.53M -5.91B -86.64M -607M -234M -3.01B -232M -227M -9.72B -24.22M -21.11M -19.89M -18.11M -33.95M -2.32B -34M -238M -91.79M -1.18B -90.96M -88.95M -3.81B
Net Debt - -
Logo Prenetics Global Limited
Prenetics Global Ltd is a company principally engaged in the provision of diagnostic and preventive products and services. The Company operates its business through two segments. The Diagnostics segment is mainly engaged in the sale of precision oncology testing services. The Prevention segment is mainly engaged in the design and sale of genetics testing, including update services, and stool-based deoxyribonucleic acid (DNA) tests for early colorectal cancer screening. The Company's products and services include CircleDNA, ACTOnco, ACTHRD and other products. The in-house developed consumer genetic testing product, CircleDNA, offers comprehensive DNA tests capitalizing on in-house developed testing algorithm. ACTOnco is a comprehensive cancer test used to guide treatment selection for major solid tumors. ACTHRD is a test for the homologous recombination deficiency status of cancer patients. The Company is also engaged in consumer health products by a new health and wellness brand IM8.
Employees
98
Date Price Change Volume
21/09/26 $24.34 +0.62% 112,652
18/09/26 $24.19 0.00% 123,914
17/09/26 $24.19 +9.85% 279,578
16/09/26 $22.02 -4.59% 247,042
15/09/26 $23.08 -4.31% 179,492
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
24.34USD
Average target price
35.86USD
Spread / Average Target
+47.32%

Quarterly revenue - Rate of surprise

-40%: Exceptional extension
d
:
:
SEIZE THE OFFER!